"A key feature of our method is blind docking, which predicts how the redesigned protein interacts with its ligand without the need for predefined binding site information," Hy said. "This ...

Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein ...

David Baker's group at the University of Washington, Seattle, U.S., have developed a novel deep learning method, RoseTTAFold All-Atom (RFAA), for prediction and design of complexes of proteins ...

“A key feature of our method is blind docking, which predicts how the redesigned protein interacts with its ligand without the need for predefined binding site information ... the fidelity of binding ...

These modules allow the ProteinReDiff framework to capture intricate protein–ligand interactions, improve the fidelity of binding affinity predictions ... binding site information," Hy said.